RxDoctor Payments Data

Megan Christy, PA

Physician Assistant · Dublin, OHNPI 1891368254

Payments from drug & device makers

$7,191in general payments, 2019–2025

Across 435 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$905
  • Johnson & Johnson$815
  • AbbVie$796
  • Lundbeck LLC$703
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$627
  • Otsuka America Pharmaceutical, Inc.$604
  • plus $3K from 10 others

What the payments were for

  • Food & beverage$7,188100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,191 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$5,207
Medicare patients
36
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$26,303
Aripiprazole18$2,489
Vilazodone Hcl13$2,079
Quetiapine Fumarate61$1,373
Divalproex Sodium ErDivalproex Sodium17$711
Fluvoxamine Maleate19$678
Olanzapine14$649
Clozapine16$592
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$538
Mirtazapine23$529
Buspirone Hcl26$485
Trazodone Hcl31$354
Bupropion XlBupropion Hcl21$292
Duloxetine Hcl14$278
Risperidone26$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$796$26,30318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →